Lisa P. Rumin Lisa P. Rumin

Subscribe to Lisa P. Rumin's Posts
Lisa P. Rumin focuses her practice on antitrust, regulatory and litigation matters. She assists clients across a variety of industries and has represented numerous clients in the healthcare, pharmaceutical, and biotechnology industries. Lisa advises clients on mergers and acquisitions, including obtaining clearance from the Federal Trade Commission (FTC) and Department of Justice (DOJ), as well as counsels clients on issues regarding antitrust compliance, pricing, and distribution. Read Lisa Rumin's full bio here. 

Federal Trade Commission Zeroes in on Problematic Non-Competes


By and on Oct 5, 2020
Posted In FTC Developments, Mergers & Acquisitions

Non-compete provisions help protect a buyer’s significant investment in an acquired business. Although non-compete clauses often play a vital role in M&A deals, they are not immune from antitrust scrutiny. Since September 2019, the FTC has challenged noncompete provisions in at least three transactions. These demonstrate that the Commission and other antitrust enforcers are closely...

Continue Reading



If Past is Prologue, Ramped up Antitrust Compliance is Critical


By and on Jun 17, 2020
Posted In Cartel Enforcement, DOJ Developments, FTC Developments

The COVID-19 pandemic has brought not only a healthcare crisis, but also one of the worst economic downturns in history. As businesses emerge from this crisis, there may be increased risk that employees may cross the line and engage in anticompetitive conduct. Therefore, it is critical that companies and individuals prepare now to ensure that...

Continue Reading



FTC Continues To Zero In On Problematic M&A Noncompetes


By and on May 28, 2020
Posted In FTC Developments, Mergers & Acquisitions

Since September 2019, the Federal Trade Commission has challenged noncompete provisions in at least three transactions. These challenges demonstrate that the FTC will challenge noncompete provisions even when it concludes that the underlying transaction raises no substantive antitrust issues and when the provision relates to minority investments. Noncompete provisions help protect a buyer’s significant investment...

Continue Reading



Third Circuit: “Rigorous Analysis” Required for Class Certification in Antitrust Cases


By , and on May 21, 2020
Posted In Private Litigation

The US Court of Appeals for the Third Circuit recently concluded in In re Lamictal Direct Purchaser Antitrust Litigation that a district court’s reliance on average prices to determine class-wide impact was insufficient. Instead, courts must conduct a rigorous analysis of the facts, evidence and expert testimony at the class certification stage of litigation. Access Full Article

Continue Reading



Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA


By , and on Feb 4, 2020
Posted In Consumer Protection/Privacy, FTC Developments, Healthcare Antitrust

Today the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) released joint guidance concerning competition for biologics, including biosimilars. The joint guidance seeks to enhance competition for biologics and reduce manufacturers’ use of false or misleading statements or promotional communications concerning the efficacy or safety of biosimilars and other biologics. This guidance...

Continue Reading



STAY CONNECTED

TOPICS

ARCHIVES